Early molecular defects in human insulin resistance: Studies in healthy subjects with low insulin sensitivity

Diabetes/Metabolism Reviews

Volumn 13, Issue 3, 1997, Pages 147-162

  Trischitta, Vincenzo ^a,b   Frittitta, Lucia ^a,c   Vigneri, Riccardo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Juvenile Diabetes Foundation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER; GLYCOGEN SYNTHASE; INSULIN; INSULIN RECEPTOR; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; PROTEIN-TYROSINE KINASES; RECEPTOR, INSULIN;

EID: 0030885952     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199709)13:3<147::AID-DMR180>3.0.CO;2-F     Document Type: Review

References (111)

1. Reaven GM: Role of insulin resistance in human disease: Banting lecture 1988. Diabetes 37: 1595-1607, 1988.
2. De Fronzo RA, Bonadonna RC, and Ferrannini E: Pathogenesis of NIDDM: A balanced overview. Diabetes Care 15: 318-368, 1992.
3. Beck-Nielsen H, and Groop LC: Metabolic and genetic characterization of prediabetic states. J Clin Invest 94: 1714-1721, 1994.
4. Harris ML, Hadden WC, Knowler WC, and Bennet PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 36: 523-534, 1987.
5. Kahn CR: Insulin action, diabetogenes, and the cause of type II diabetes: Banting Lecture 1994. Diabetes 43: 1066-1084, 1994.
6. Reaven GM: The fourth Musketeer: From Alexandre Dumas to Claude Bernard. Diabetologia 38: 3-13, 1995.
7. Martin RD, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, and Kahn CR: Role of glucose and insulin resistance in the development of type II diabetes mellitus: Results of a 25-year followup study. Lancet 340: 925-929, 1992.
8. Gulli G, Ferrannini E, Stern M, Haffner S, and DeFronzo RA: The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American parents. Diabetes 41: 1575-1587, 1992.
9. Kasuga M, Karlsson FA, and Kahn CR: Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science 215: 185-190, 1982.
10. Kasuga M, Zick Y, Blithe DL, Crettaz M, and Kahn C: Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system. Nature 298: 667-672, 1982.
11. Roth RA, and Cassell MP: Insulin receptor: Evidence that it is a protein kinase. Science 219: 299-303, 1983.
12. Rosen OM: After insulin binds. Science 237: 1452, 1987.
13. Sun XJ, Rothenberg PL, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, and White MF: The structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352: 73-77, 1991.
14. Araki E, Sun XJ, Haag' BL, Chuang LM, Yang-Feng T, White MF, and Kahn CR: Human skeletal muscle insulin receptor substrate-1: Characterization of the cDNA, gene and chromosomal localization. Diabetes 42: 1041-1054, 1993.
15. White MF: The 1RS signaling system in insulin and cytokine action. Phil Trans R Soc Lond B Biol Sd 351: 1336, 181-189, 1996.
16. My ers MG Jr, and White MF: The new elements of insulin signalling: Insulin receptor substrate-1 and proteins with SH-2 domains. Diabetes 42: 643-650, 1993.
17. Lavan BE, Huhne MR, Garner CW, Anderson D, Reedijk M, Pawson T, and Leinhard GE: The association with insulin-elicited phospho-tyrosine proteins with src homology 2 domains. J Biol Chem 267: 11631-11636, 1992.
18. Backer JM, Myers MG Jr, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M, Hu P, Margolis B, Skolnik EY, Schlessinger J, and White MF: The phosphatidylinositol 3-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 11: 3469-3479, 1992.
19. Stone RL, and Dixon JE: Protein-tyrosine phosphatases. J Biol Chem 269: 31323-31326, 1994.
20. Schlessinger J: How receptor tyrosine kinase activates Ras. Trends Biochem Sci 18: 273-275, 1993.
21. Korn LJ, Siebel CW, McCormick F, and Roth RA: Ras p21 as a potential mediator of insulin action in Xenopus oocytes. Science 236: 840-843, 1987.
22. Bar-Sagi D: The Sos (Son of sevenless) protein. TEM 5: 165-169, 1994.
23. Skolnik EY, Lee CH, Batzer AG, Vicentini LM, Zhou M, Daly RJ, Myers MG Jr, Backer JM, Ullrich A, White MF, and Schlessinger J: The SH2/SH3 domain containing protein GRB2 interacts with tyrosine phosphorylated IRS1 and Shc: Implications for insulin control of ras signaling. EMBO J 12: 1929-1936, 1993.
24. McCormick F: Signal transduction: How receptors turn Ras on. Nature 363: 15-16, 1993.
25. Macara IG: The ras superfamily of molecular switches. Cell Signal 3: 179-187, 1991.
26. Der CJ: The ras family of oncogenes. Cancer Treat Res 47: 73-119, 1989.
27. Kovacina KS, Yonezawa K, Brautigan DL, Tonks NK, Rapp UR, and Roth RA: Insulin activates the kinase activity of the raf-1 proto-oncogene by increasing its serine phosphorylation. J Biol Chem 265: 12115-12118, 1990.
28. Zhang X, Settleman J, Kyriaks JM, TakeuchiSuzuki E, Elledge SJ, Marshall MS, Bruder JT, Rapp UR, and Avruch J: Normal and oncogenic p21-ras proteins binds to the amino-terminal regulatory domain of c-Raf-1. Nature 364: 308-313, 1993.
29. Dent P, Lavoinne A, Nakielny S, Caudwell FB, Watt P, and Cohen P: The molecular mechanisms by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348: 302-308, 1990.
30. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, and Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 271: 665-668, 1996.
31. Rynet C, and Kahn CR: Rad: A member of the ras family overexpressed in muscle of type II diabetic humans. Science 262: 1441-1444, 1993.
32. Bollag GE, Roth RA, Beaudoin J, Mochly-Rosen D, and Koshland DE: Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Proc Natl Acad Sci USA 83: 5822-5824, 1986.
33. Anderson CM, and Olefsky JM: Phorbol estermediated protein kinase C interaction with wildtype and COOH-terminal truncated insulin receptors. J Biol Chem 266: 21760-21764.
34. Ahmad F, Considine RV, and Goldstein BJ: Increased abundance of the receptor-type protein-tyrosine phasphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. J Clin Invest 95: 2806-2812, 1995.
35. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spencer S, Grupe A, Henzel W, Sewart TA, Reaven GM, and Goldfine ID: Membrane glycoprotein PC-1 and insulin resist-ance in non-insulin dependent diabetes mellitus. Nature 373: 448-451, 1995.
36. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, and Simsolo RB: The expression of tumour necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95: 2111-2119, 1995.
37. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, and Spiegelman BM: Increased adipose tissue expression of tumour necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995.
38. Saghizadeh M, Ong JM, Garvey WT, Henry RR, and Kern PA: The expression of TNF-α by human muscle: Relationship to insulin resistance. J Clin Invest 97: 1111-1116, 1996.
39. Considine RV, Nyce MR, Allen LE, Morales LM, Triester S, Serrano J, Colberg J, Lanza-Jacoby S, and Caro JF: Protein kinase C is increased in the iver of humans and rats with non-insulin-dependent diabetes mellitus: An alteration not due to hyperglycemia. J Clin Invest 95: 2938-2944, 1995.
40. Whitehead JP, Humphreys PJ, Maasen JA, Poller DE, Krok A, and O'Rahilly S: Increased PC-1 phosphodiesterase activity in patients with postreceptor insulin resistance but not in patients with insulin receptor mutations. Diabetologia 38 (Suppl 1): 65A (Abstract), 1995.
41. Youngren JF, Maddux BA, Sasson S, Sbraccia P, Tapscott EB, Swanson MS, Dohm GL, and Goldfine ID: Skeletal muscle content of membrane glycoprotein PC-1 in obesity: relationship to muscle glucose transport. Diabetes 45: 1-6, 1996.
42. Frittitta L, Youngren J, Vigneri R, Maddux BA, Trischitta V, and Goldfine ID: PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: Relationship to insulin receptor tyrosinekinase and whole body insulin sensitivity. Diabetologia 39: 1190-1195, 1996.
43. Frittitta L, Youngren J, Sbraccia P, D'Adamo M, Buongiorno A, Vigneri R, Goldfine ID, and Trischitta V: Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-a gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia, 40: 282-289, 1997.
44. Caro JF, Shina MK, Raju SM, Ittop O, Davies WJ, Flickinger EG, Meelheim D, Dohm GL. et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without non-insulin-dependent diabetes. J Clin Invest 79: 1333-1337, 1987.
45. Arner P, Pollare T, Lithell H, and Livingston JN: Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 437-440, 1987.
46. Obermaier-Kusser B, White MF, Pongratz D, Su Z, Ermel B, Mühlbacher C, and Häring HU: A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin-dependent diabetes mellitus. J Biol Chem 264: 9497-9504, 1989.
47. Nyomba BL, Ossowski VM, Bogardus C, and Mott DM: Insulin-sensitive tyrosine-kinase:relationship with in vivo insulin action in humans. Am J Physiol 258: (Endocrinol Metab 21): E964-E974, 1990.
48. Maegawa H, Shigeta Y, Egawa K, and Kobayashi M: Impaired autophosphorylation of insulin receptors from abdominal skeletal muscle in non obese subjects with NIDDM. Diabetes 40: 815-819, 1991.
49. Nolan JJ, Freidenberg G, Henry R, Reichart D, and Olefsky JM: Role of human skeletal muscle receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. J Clin Endocrinol Metab 78: 471-477, 1994.
50. Klein HH, Vestegaard H, Kotzke G, and Pedersen O: Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM. Diabetes 44: 1310-1317, 1995.
51. Freidenberger GR, Henry RR, Klein HH, and Olefsky JM: Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic subjects. J Clin Invest 79: 240-250, 1987.
52. Sihna MK, Pories WJ, Flickinger EG, Meelheim D, and Caro JF: Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes 36: 620-625, 1987.
53. Takayama S, Kahn CR, Kubo K, and Foley JE: Alterations in insulin receptor autophosphorylation in insulin resistance: Correlation with altered sensitivity to glucose transport and antilipolysis to insulin. J Clin Endocrinol Metab 66: 992-997, 1988.
54. Caro JF, Ittoop O, and Pories WJ: Studies on the mechanism of insulin resistance in the liver from humans with non-insulin-dependent diabetes. J Clin Invest 78: 249-258, 1986.
55. Goodyear LJ, Giorgino F, Sherman A, Carey J, Smith RJ, and Dohm GL: Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinas activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95: 2195-2204, 1995.
56. Taylor SI, Cama A, Accili D, Barbetti F, Quon MH, Sierra ML, Suzuki Y, Koller E, Levy-Toledano R, Wertheimer E, Moncada VY, Kadowaki H, and Kadowaki T: Mutations in the insulin receptor gene. Endocr Rev 13: 566-595, 1992.
57. O'Rahilly S, Choi WH, Patel P, Turner RC, Flier JS, and Moller DE: Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms. Diabetes 40: 777-783, 1991.
58. Cocozza S, Porcellini A, Riccardi G, Monticelli A, Condoreli G, Ferrara A, Pianese L, Miele C, Capaldo B, Beguinot F, and Varrone S: NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene. Diabetes 41: 521-526, 1992.
59. Handberg A, Vaag A, Vincent J, and Beck-Nielsen H: Decreasd tyrosine kinase activity in partially purified insulin receptor from skeletal muscle of young, non-obese first degree relatives of patients with type 2 (non-insulin-depdendent) diabetes mellitus. Diabetologia 36: 668-674, 1993.
60. Grasso G, Frittitta L, Anello M, Russo P, Sesti G, and Trischitta V: Insulin receptor tyrosinekinase activity is altered in both muscle and adipose tissue from nonobese normoglycemic insulin resistant subjects. Diabetologia 38: 55-61, 1995.
61. Moeller DE, Yokota A, Caro JF, and Flier J: Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 3: 1263-1269, 1989.
62. McClain DA: Different ligand affinities of the two human insulin receptor splice variants are reflected in parallel changes in sensitivity for insulin action. Mol Endocrinol 5: 734-739.
63. Yamaguchi Y, Flier JS, Yokota A, Benecke H, Backer J, and Moeller DE: Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese Hamster Ovary cells. Endocrinology 12: 2058-2063, 1991.
64. Vogt B, Carrascosa JM, Ermel B, Ullrich A, and Haring HU: The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. BBRC 177: 1013-1018, 1991.
65. Mosthaf LB, Vogt H, Haring HU, and Ullrich A. Altered expression of insulin receptor types A and B in the skeletal muscle of non insulin dependent diabetes mellitus patients. Proc Nat Acad Sci USA 88: 4728-4730, 1991.
66. Norgren S, Zierath J, Galuska D, Wallberg-Henriksson H, and Luthman H. Differences in the ratio of RNA encoding two isoforms of the insulin receptor between control and NIDDM patients. Diabetes 42: 675-681, 1993.
67. Kellerer M, Sesti G, Seffer E, Obermaier-Kusser B, Pongratz DE, Mosthaf L, and Haring HU: Altered pattern of insulin receptor isotypes in skeletal muscle membranes of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36: 628-632, 1993.
68. Sesti G, D'Alfonso R, Vargas Punti MD, Frittitta L, Trischitta V, Liu YY, Borboni P, Longhi R, Montemurro A, and Lauro R. Peptide-based radioimmunoassay for the two isoforms of the human insulin receptor. Diabetologia 38: 445-453, 1995.
69. Benecke H, Flier JS, and Moller DE: Alternatively spliced variants of the human insulin receptor protein. J Clin Invest 89: 2066-2070, 1992.
70. Anderson CM, Henry RR, Knudson PE, Olefsky JM, and Webster NJG: Relative expression of insulin receptor isoforms does not differ in lean, obese, and non insulin dependent diabetes mellitus subjects. J Clin Endocrinol Metab 72: 1380-1382, 1993.
71. Hansen T, Bjoerbeak C, Vestergaard H, Gronskov K, Bak JF, and Pedersen O: Expression of insulin receptor spliced variants and their functional correlates in muscle from patients with non insulin dependent diabetes mellitus. J Clin Endocrinol Metab 77: 1500-1505, 1993.
72. Mosthaf LB, Erikson J, Haring HU, Groop L, Widen E, and Ullrich A: Insulin receptor isotype expression correlates with risk of non insulin dependent diabetes. Proc Natl Acad Sci USA 90: 2633-2636, 1993.
73. Jochen AL, Berhanu P, and Olefsky JM: Insulin internalization and degradation in adipocytes from normal and type II diabetes subjects. J Clin Endocrinol Metab 62: 268-272, 1986.
74. Trischitta V, Gullo D, Squatrito S, Pezzino V, Goldfine ID, and Vigneri R: Insulin internalization into monocytes is decreased in patients with type II diabetes mellitus. J Clin Endocrinol Metab 62: 522-529, 1986.
75. Trischitta V, Benzi L, Brunetti A, Cecchetti P, Marchetti P, Vigneri R, and Navalesi R: Intracellular insulin processing is altered in monocytes from patients with type II diabetes mellitus. J Clin Endocrinol Metab 64: 914-920, 1987.
76. Trischitta V, Brunetti A, Chiavetta A, Benzi L, Pap V, and Vigneri R: Defects in insulin-receptor internalization and processing in monocytes of obese subjects and obese NIDDM patients. Diabetes 38: 1579-1584, 1989.
77. Frittitta L, Grasso G, Munguira ME, Vigneri R, and Trischitta V: Insulin receptor tyrosine-kinase activity is reduced in monocytes from non-obese normoglycemic insulin-resistant subjects. Diabetologia 36: 1163-1167.
78. Freidenberger GR, Reichart D, Olefsky JM, and Henry RR: Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. J Clin Invest 82: 1398-1406, 1988.
79. Ofei F, Hurel S, Newkirk J, Sopwith M, and Taylor R: Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881-885, 1996.
80. Grupe A, Alleman J, Goldfine ID, Sadick M, and Stewart TA: Inhibition of insulin receptor phosphorylation by PC-1 is not mediated by the hydrolysis of adenosine triphosphate or the generation of adenosine. J Biol Chem 270: 22085-22088, 1995.
81. Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, Maddux B, Goldfine ID, and Vigneri R: Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells in associated with inhibition of insulin receptor tyrosine-kinase activity. Mol Endocrinol 10: 1318-1326, 1996.
82. Kahn BB: Glucose transport: Pivotal step in insulin action. Lilly lecture 1995. Diabetes 45: 1644, 1996.
83. Mandarino LJ, Wright KS, Verity LS, Nichols J, Bell JM, Kolterman OG, and Beck-Nilsen H: Effects of insulin on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. J Clin Invest 80: 655-661, 1987.
84. Dohm GL, Tapscott EB, Pories WJ, Dabbs DJ, Flickinger EG, Meelheim D, Fushiki T, Atkinson SM, Elton CW, and Caro JF: An in vitro human muscle preparation suitable for metabolic studies. J Clin Invest 82: 486-494, 1988.
85. 31P Nuclear magnetic resonance measurements of muscle glucose-6-phosphate. J Clin Invest 96: 2820-2827, 1992.
86. Bonadonna RC, Del Prato S, Saccomani MP, Gulli G, Ferrannini E, Bier D, Cobelli C, and De Fronzo RA: Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Invest 92: 486-494, 1993.
87. Henry RR, Abrams L, Nikoulina S, and Ciaraldi TP: Insulin action and glucose metabolism in non-diabetic control and NIDDM subjects: Comparison using human skeletal muscle and cell cultures. Diabetes 44: 936-946, 1995.
88. Eriksson J, Frassila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, and Groop L: Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321: 337-343, 1989.
89. Kusari J, Verma US, Buse JB, Henry RR, and Olefsky JM: Analysis of the gene sequences of the insulin receptor and the insulin sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellirus. J Clin Invest 88: 1323-1330, 1991.
90. Buse JB, Yasuda K, Lay TP, Seo S, Olson AL, Pessin JE, Karam JH, Seino S, and Bell GI: Human GLUT-4/muscle-fat glucose-transporter gene. Diabetes 41: 1436-1445, 1992.
91. O'Rahillys, Krook A, Morgan R, Rees A, Flier JS, and Moller DE: Insulin receptor and insulinresponsive glucose transporter (Glut 4) mutations and polymorphisms in a Welsh type 2 (non-insulin-dependent) diabetic population. Diabetologia 35: 486-491, 1992.
92. Dohm G, Elton CW, Friedman JE, Pilch PF, Pories WJ, Atkinson SM, and Caro JF: Decreased expression of glucose transporter in muscle from insulin-resistant patients. Am J Physiol 280: E459-463, 1991.
93. Vogt B, Muhlbahcer C, Carrascosa J, Obermaier-Kusser B, Seffer E, Mushack J, Pongratz D, and Haring HU: Subcellular distribution of GLUT 4 in the skeletal muscle of lean type 2 (non-insulin-dependent) diabetic patients in the basal state. Diabetologia 35: 456-463, 1992.
94. Pedersen O, Bak JF, Andersen PH, Lund S, Moller DE, Flier JS, and Kanh BB: Evidence against altered expression of Glut 1 or Glut 4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 39: 865-870, 1990.
95. Handerberg A, Vaag A, Damsbo P, Beck-Nielsen H, and Vinten J: Expression of insulin regulatable glucose transporters in skeletal muscle from type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33: 625-627, 1990.
96. Garvey WT, Maianu L, Hancock JA, Golichowski AM, and Baron A: Gene expression of Glut 4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 41: 465-475, 1992.
97. Eriksson J, Koranyi I, Bourey R, Schalin Jantii C, Widen E, Mueckler M, Permutt AM, and Groop LC: Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (Glut-4) gene in skeletal muscle. Diabetologia 35: 143-147, 1992.
98. Frittitta L, Gliozzo BM, Foti D, Astuto M, Basile F, Vigneri R, and Trischitta V: Heterogeneity of Glut-4 content in adipose and muscle tissue of moderately obese patients with or without non-insulin dependent diabetes mellitus. Diabetes Nutr Metab 7: 17-29, 1994.
99. Koranyi LI, Bourey RE, Vuorinen-Markkola H, Koivisto VA, Mueckler M, Permutt MA, and Yki-Järvinen H: Level of skeletal muscle glucose transporter protein correlates with insulinstimulated whole body glucose disposal in man. Diabetologia 34: 763-765, 1991.
100. Houmard JA, Weidner MD, Dolan PL, Legget-Frazier N, Gavigan KE, Hickey MS, Tyndall GL, Zheng D, Alshami A, and Dohm GL: Skeletal muscle GLUT 4 protein concentration and aging in humans. Diabetes 44: 555-560, 1995.
101. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, and Ciaraldi TP. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 87: 1072-1081, 1991.
102. Sinha MK, Raineri-Maldonado C, Buchanan C, Pories WJ, Carter Su C, Pilch PF, and Caro JF: Adipose tissue glucose transporters in NIDDM: Decreased levels of muscle/fat isoform. Diabetes 40: 472-477, 1991.
103. Garvey TA, Maianu L, Hong-Zhu J, Hancock JA, and Golichowski AM: Multiple defects in the adipocytes glucose transport system cause cellular insulin resistance in gestational diabetes. Diabetes 42: 1773-1785, 1993.
104. Frittitta L, Grasso G, Vigneri R, and Trischitta V: A reduced GLUT 4 content in adipose tissue is not an early defect in the development of human insulin resistance. Diabetes Nutr Metab 8: 262-266, 1995.
105. 13C nuclear magnetic resonance spectroscopy. N Engl J Med 322: 223-228, 1990.
106. Damsbo P, Vaag A, Hother-Nielsen O, and Beck-Nielsen H: Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 diabetes. Diabetologia 34: 239-245, 1991.
107. Wells AM, Sutcliff IC, Johnson AB, and Taylor R: Abnormal activation of glycogen synthesis in fibroblasts from NIDDM subjects. Diabetes 42: 583-589, 1993.
108. Vaag A, Henriksen JE, and Beck-Nielsen H: Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 89: 782-788, 1992.
109. Schalin-Jantti C, Harkonen M, and Groop LC: Impaired activation of glycogen synthase in people at increased risk for developing NIDDM. Diabetes 41: 598-604, 1992.
110. Groop LC, Kankuri M, Schalin-Jantii C, Ekstrand A, Nikula-Ijas P, Widen E, Kuismanen E, Eriksson J, Franssila-Kallunki A, Saloranta C, and Koskimies S: Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 328: 10-14, 1993.
111. Elbein SC, Hoffman M, Ridinger D, Otterud B, and Leppert M: Description of a second microsatellite marker and linkage analysis of the muscle glycogen synthase locus in familial NIDDM. Diabetes 43: 1061-1066, 1994.